GKWIM
DFTX

Gerber Kawasaki Wealth & Investment Management’s Definium Therapeutics DFTX Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,036
Closed -$21K – 272
2021
Q4 		$21K Buy
1,036
+1,035
+103,500% +$33K ﹤0.01% 268
2021
Q3 		$9K Sell
1
-1,133
-100% -$49K ﹤0.01% 660
2021
Q2 		$58K Buy
+1,134
New +$59.5K 0.01% 243

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's DFTX Position: Q1 2022 in Review

Gerber Kawasaki Wealth & Investment Management sold out of Definium Therapeutics (DFTX) in Q1 2022, closing a stake of 1,036 shares — an estimated $21K sold.

Gerber Kawasaki Wealth & Investment Management first reported a position in DFTX in Q2 2021 and held it in 3 quarters. The position peaked at $58K in Q2 2021. 159 funds tracked by Wall St. Rank hold DFTX as of Q1 2022.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining Definium Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 1,036 Definium Therapeutics shares in Q1 2022, an estimated $21K.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in Definium Therapeutics in Q2 2021 and held it in 3 quarters.
  • Gerber Kawasaki Wealth & Investment Management's Definium Therapeutics position peaked at $58K in Q2 2021.
  • 159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2022.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q1 2022, filed 12 May 2022.